UNSPSC 51285802: Hexamidine

This classification denotes an antibiotic with the molecular formula C20H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3483C2H13H, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-phenyl- but more generally known as hexamidine, which bears US NIH Compound Identifier 4909. European Medicines Agency schedules Hexamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08029MIG.

UNSPSC 51285802 Hexamidine, a Commodity code, nominally addresses a single pharmaceutical ingredient, but recent state and local procurement activity under this code shows little alignment with hexamidine itself. The opportunities posted show purchasing of naloxone, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which target hexamidine as a primary commodity. State and local governments appear to have tagged these solicitations with this code as a catch-all for pharmaceutical procurement rather than reflecting genuine demand for hexamidine specifically. The issuing bodies span diverse jurisdictions: Seminole County, Florida (public health); the Texas Health and Human Services Commission (state health agency); the City of Tampa (municipal fire department); and the Minnesota Multistate Cooperative Purchasing Alliance (state cooperative purchasing vehicle serving multiple jurisdictions including Oregon). None of the recent opportunities target hexamidine acquisition.

Recent activity shows no viable opportunities tied directly to hexamidine procurement. The Seminole County IFB (IFB60459723LAS, due July 26, 2026 with posted date June 30, 2026) sought naloxone and drug deactivation systems; the Texas HHS RFI (HHS0017013) explored direct-to-manufacturer prescription contracting; the City of Tampa IFB (26P00145, due March 13, 2026) procured medical and first aid supplies for emergency response with an estimated contract value of $700,000.00 under a sheltered market set-aside for certified Small Local Business Enterprises; and the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) sought generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The code shows activity across Florida, Texas, Minnesota, and Oregon, but the mismatch between the code's nominal scope (hexamidine) and the actual work being solicited signals either systematic miscoding or use of this commodity code as a fallback category for pharmaceutical purchases that do not fit more specific codes. Firms pursuing pharmaceutical sales to state and local health agencies should monitor broader pharmaceutical and OTC procurement codes rather than relying on this code as a reliable signal for hexamidine demand.